Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women

European Journal of Human Genetics

Volumn 20, Issue 5, 2012, Pages 559-564

  Gartland, Alison ^a   Skarratt, Kristen K ^b   Hocking, Lynne J ^c   Parsons, Claire ^c   Stokes, Leanne ^b   Jørgensen, Niklas Rye ^d   Fraser, William D ^e   Reid, David M ^c   Gallagher, James A ^f   Wiley, James S ^b,g  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d Mental Health Center Glostrup   (Denmark)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

LS BMD; P2RX7; single nucleotide polymorphisms

Indexed keywords

PURINERGIC P2X7 RECEPTOR;

ADULT; ARTICLE; BONE DENSITY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

BONE DENSITY; FEMALE; HUMANS; LUMBOSACRAL REGION; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2X7; SPINE;

EID: 84859900260     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.245     Document Type: Article

References (52)

1. Burnstock G, Williams M: P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharmacol Exp Ther 2000; 295: 862-869.
2. Agrawal A, Buckley KA, Bowers K et al: The effects of P2X7 receptor antagonists on the formation and function of human osteoclasts in vitro. Purinergic Signal 2010; 6: 307-315.
3. Bowler WB, Buckley KA, Gartland A et al: Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling. Bone 2001; 28: 507-512. (Pubitemid 32410002)
4. Buckley KA, Hipskind RA, Gartland A et al: Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. Bone 2002; 31: 582-590. (Pubitemid 35449700)
5. Gartland A, Buckley KA, Bowler WB et al: Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif Tissue Int 2003; 73: 361-369. (Pubitemid 37409423)
6. Gartland A, Hipskind RA, Gallagher JA et al: Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J Bone Miner Res 2001; 16: 846-856. (Pubitemid 32332294)
7. Jorgensen NR, Henriksen Z, Sorensen OH et al: Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem 2002; 277: 7574-7580. (Pubitemid 34953156)
8. Orriss IR, Utting JC, Brandao-Burch A et al: Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology 2007; 148: 4208-4216. (Pubitemid 47295696)
9. Panupinthu N, Rogers JT, Zhao L et al: P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol 2008; 181: 859-871. (Pubitemid 351786989)
10. Panupinthu N, Zhao L, Possmayer F et al: P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. J Biol Chem 2007; 282: 3403-3412. (Pubitemid 47084361)
11. Gallagher JA: ATP P2 receptors and regulation of bone effector cells. J Musculoskelet Neuronal Interact 2004; 4: 125-127.
12. Di Virgilio F: The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today 1995; 16: 524-528.
13. Mackenzie AB, Young MT, Adinolfi E et al: Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. J Biol Chem 2005; 280: 33968-33976. (Pubitemid 41443117)
14. Ferrari D, Pizzirani C, Adinolfi E et al: The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006; 176: 3877-3883. (Pubitemid 44264361)
15. Mehta VB, Hart J, Wewers MD: ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001; 276: 3820-3826.
16. Rampe D, Wang L, Ringheim GE: P2X7 receptor modulation of beta-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J Neuroimmunol 2004; 147: 56-61. (Pubitemid 38114947)
17. Sluyter R, Dalitz JG, Wiley JS: P2X7 receptor polymorphism impairs extracellular adenosine 5′-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun 2004; 5: 588-591. (Pubitemid 39529976)
18. Humphreys BD, Dubyak GR: Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 1998; 64: 265-273. (Pubitemid 28354990)
19. Mundy GR: Osteoporosis and inflammation. Nutr Rev 2007; 65: S147-S151.
20. Rifas L: Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcif Tissue Int 1999; 64: 1-7.
21. Naemsch LN, Dixon SJ, Sims SM: Activity-dependent development of P2X7 current and Ca2+ entry in rabbit osteoclasts. J Biol Chem 2001; 276: 39107-39114.
22. Ohlendorff SD, Tofteng CL, Jensen JE et al: Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics 2007; 17: 555-567. (Pubitemid 46905222)
23. Korcok J, Raimundo LN, Ke HZ et al: Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res 2004; 19: 642-651. (Pubitemid 41071225)
24. Grey A, Banovic T, Naot D et al: Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Endocrinology 2001; 142: 1098-1106. (Pubitemid 32202819)
25. Masiello LM, Fotos JS, Galileo DS et al: Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells. Bone 2006; 39: 72-82. (Pubitemid 43831774)
26. Radeff JM, Nagy Z, Stern PH: Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. J Bone Miner Res 2004; 19: 1882-1891. (Pubitemid 41103440)
27. Gartland A, Buckley KA, Hipskind RA et al: Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice. Crit Rev Eukaryot Gene Expr 2003; 13: 243-253. (Pubitemid 38009173)
28. Nicke A, Kuan YH, Masin M et al: A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem 2009; 284: 25813-25822.
29. Ke HZ, Qi H, Weidema AF et al: Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol 2003; 17: 1356-1367. (Pubitemid 36819956)
30. Li J, Liu D, Ke HZ et al: The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem 2005; 280: 42952-42959. (Pubitemid 43049258)
31. Buckley KA, Golding SL, Rice JM et al: Release and interconversion of P2 receptor agonists by human osteoblast-like cells. Faseb J 2003; 17: 1401-1410. (Pubitemid 36935655)
32. Shemon AN, Sluyter R, Fernando SL et al: A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 2006; 281: 2079-2086. (Pubitemid 43845796)
33. Gu BJ, Wiley JS: Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 2006; 107: 4946-4953. (Pubitemid 43882649)
34. Gu BJ, Zhang W, Worthington RA et al: A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-11142. (Pubitemid 38089296)
35. Wiley JS, Dao-Ung LP, Li C et al: An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 2003; 278: 17108-17113. (Pubitemid 36799588)
36. Gu BJ, Sluyter R, Skarratt KK et al: An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 2004; 279: 31287-31295. (Pubitemid 39037794)
37. Skarratt KK, Fuller SJ, Sluyter R et al: A 5¢ intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1-2% of the Caucasian population. FEBS Lett 2005; 579: 2675-2678. (Pubitemid 40615676)
38. Cabrini G, Falzoni S, Forchap SL et al: A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 2005; 175: 82-89. (Pubitemid 40884304)
39. Fernando SL, Saunders BM, Sluyter R et al: A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 2007; 175: 360-366.
40. MacDonald HM, McGuigan FA, New SA et al: COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss. J Bone Miner Res 2001; 16: 1634-1641. (Pubitemid 32786432)
41. Garton MJ, Torgerson DJ, Donaldson C et al: Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study. BMJ 1992; 305: 82-84.
42. Torgerson DJ, Garton MJ, Donaldson C et al: Recruitment methods for screening programmes: trial of an improved method within a regional osteoporosis study. BMJ 1993; 307: 99. (Pubitemid 23189570)
43. Grant SF, Reid DM, Blake G et al: Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 1996; 14: 203-205. (Pubitemid 26338805)
44. Rassendren F, Buell GN, Virginio C et al: The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 1997; 272: 5482-5486. (Pubitemid 27102368)
45. Jørgensen NR, Husted LB, Skarratt KK et al: Single nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Hum Genet 2011; epub ahead of print, doi:10.1038/ejhg.2011.253.
46. Mrazek F, Gallo J, Stahelova A et al: Functional variants of the P2RX7 gene, aseptic osteolysis, and revision of the total hip arthroplasty: a preliminary study. Hum Immunol 2010; 71: 201-205.
47. Gu BJ, Rathsam C, Stokes L et al: Extracellular ATP dissociates nonmuscle myosin from P2X(7) complex: this dissociation regulates P2X(7) pore formation. Am J Physiol Cell Physiol 2009; 297: C430-C439.
48. Kim M, Jiang LH, Wilson HL et al: Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 2001; 20: 6347-6358. (Pubitemid 33078708)
49. Turner CH, Robling AG: Mechanisms by which exercise improves bone strength. J Bone Miner Metab 2005; 23 (Suppl): 16-22.
50. Guo C, Masin M, Qureshi OS et al: Evidence for functional P2X4/P2X7 heteromeric receptors. Mol Pharmacol 2007; 72: 1447-1456. (Pubitemid 350146082)
51. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S et al: Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008; 358: 2355-2365. (Pubitemid 351749159)
52. Fuller SJ, Stokes L, Skarratt KK et al: Genetics of the P2X7 receptor and human disease. Purinergic Signal 2009; 5: 257-262.